We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info

Confirm

Driving innovative solutions with
Adhesys Medical

In April 2017, we acquired Adhesys Medical and its innovative pipeline of surgical sealants alongside the supporting technology. The technology fulfils our desire to go beyond drug development to drive genuine innovation.

This acquisition provided us with a truly unique technology platform. The surgical sealants could provide alternatives to the traditional methods for closing both wounds to the skin and inside the body during surgery. In addition, the combination of the technology’s bonding strength, fast sealing and flexibility is not currently available in any other product.

Our acquisition represented the perfect marriage; the deep know how, entrepreneurial spirit and high agility of Adhesys Medical, combined with our unique experience of running tailored clinical programmes to bring new solutions to the market in complex cross-functional settings.

“We believe this sealant will provide an innovative alternative to traditional wound closing techniques. Through its high flexibility it may enhance patient comfort after surgery.”

Gabriel Baertschi

Chief Executive Officer, Grünenthal Group

We are keen to learn from Adhesys Medical’s existing culture; innovation is often the domain of smaller start-up companies so to foster this entrepreneurial mindset, we decided to leave Adhesys Medical as an independent company.

CUTIS topical skin adhesive – learn more about CUTIS

The frontrunner of Adhesys Medical’s sealant pipeline is Flix®, an innovative topical skin adhesive for surgical use. It received CE-Certification in 2018. “We believe this sealant will provide an innovative alternative to traditional wound closing techniques”, CEO Gabriel Baertschi said on the occasion of the certification. “Through its high flexibility it may enhance patient comfort after surgery.” And Dr. Klaus-Dieter Langner, Chief Scientific Officer Grünenthal, added, “Obtaining this certification is a great success for our Research & Development organization, which drives the technological and clinical development of our surgical sealant pipeline. We are now looking forward to further developing our technology platform and expanding the possible fields of application.”

“Obtaining this certification is a great success for our Research & Development organization, which drives the technological and clinical development of our surgical sealant pipeline. We are now looking forward to further developing our technology platform and expanding the possible fields of application.”

VIVO surgical sealant – learn how VIVO works

VIVO, designed for wound closure inside the body, is in pre-clinical stage.